← Back to headlines
Eli Lilly Receives 'Buy' Rating Reaffirmation After Successful Trial
Truist has reaffirmed its 'Buy' rating for Eli Lilly (LLY) following the success of a recent trial. The positive trial results are expected to bolster investor confidence in the pharmaceutical giant.
3 May, 08:51 — 3 May, 08:51
Sources
Showing 1 of 1 sources
